The fastest weight gain with antipsychotic use occurs within the first 6 months of initiating treatment. There is no clear relationship between weight gain and antipsychotic dose, at least within therapeutic ranges. Olanzapine, chlorpromazine, and clozapine carry a high risk for weight gain. Ziprasidone, lurasidone, amisulpride, asenapine, and haloperidol have a low risk of weight gain. Quetiapine, risperidone, and paliperidone carry a medium risk of weight gain.
Haddad, P (2017). Antipsychotic medication and weight gain. British Association for Psychopharmacology. https://www.bap.org.uk/articles/antipsychotic-medication-and-weight-gain/
Blackburn, G. L. (2000). Weight gain and antipsychotic medication. The Journal of clinical psychiatry, 61, 36-41. https://europepmc.org/abstract/med/10811242
Our Next Journal Club Scheduled for May 16:
1.50 AMA PRA Category 1 Credits (for first 6 journal clubs): CME Credits will increase with upcoming journal club videos.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute, LLC and Psychiatry Education Forum LLC. The PeerPoint Medical Education Institute, LLC is accredited by the ACCME to provide continuing medical education for physicians.
The PeerPoint Medical Education Institute, LLC designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.